Cl[C:2]1[N:3]=[C:4]2[N:12]([CH2:13][C:14](=[O:18])[CH:15]([CH3:17])[CH3:16])[C@H:11]([C:19]([F:22])([F:21])[F:20])[CH2:10][CH2:9][N:5]2[C:6](=[O:8])[CH:7]=1.Cl.[C@H:24]12[CH2:30][C@H:27]([NH:28][CH2:29]1)[CH2:26][O:25]2.C(N(CC)CC)C>C(OCC)(=O)C>[CH3:16][CH:15]([CH3:17])[C:14](=[O:18])[CH2:13][N:12]1[C:4]2=[N:3][C:2]([N:28]3[CH2:29][C@@H:24]4[CH2:30][C@H:27]3[CH2:26][O:25]4)=[CH:7][C:6](=[O:8])[N:5]2[CH2:9][CH2:10][C@H:11]1[C:19]([F:22])([F:21])[F:20]220 mg (0.51 mmol) of (8S)-2-chloro-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 105.99 mg (0.78 mmol) of (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane hydrochloride are mixed together. The powder obtained is placed in a tube and 227 μl (1.63 mmol) of triethylamine are added. The tube is sealed and heated at 130° C. in an oil bath for 3 hours. The crude product obtained is taken up in ethyl acetate and the organic phase is washed with water, dried over magnesium sulfate and then evaporated to dryness. The residue is purified by chromatography on silica gel (eluent: 95/5 EtOAc/MeOH) to give 100 mg of (8S)-9-(3-methyl-2-oxobutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, the characteristics of which are as follows:
読み込み中…